California-based Gritstone Oncology has struck a deal with Massachusetts biotechnology company bluebird bio, in order to develop cell therapy cancer treatments. We look forward to collaborating with the bluebird bio team in order to develop innovative treatments for patients in need.” The agreement is the first of its kind for Bluebird, which was founded by Dr. David L. Cohen and his wife, Susan Cohen, who are both oncologists. Grtistone will receive $20m up-front funding and $10m in series C preferred equity investment as part of the agreement.
California-based Gritstone Oncology has struck a deal with Massachusetts biotechnology company bluebird bio, in order to develop cell therapy cancer treatments. The agreement is the first of its kind for Bluebird, which was founded by Dr. David L. Cohen and his wife, Susan Cohen, who are both oncologists. Grtistone will receive $20m up-front funding and $10m in series C preferred equity investment as part of the agreement.